The Use of Conventional Salvage Chemotherapy Before Dose-Intensive Cytotoxic Therapy and Autologous Transplantation for Aggressive-Histology Lymphoma: A Case for Re-Evaluation

References

• Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328(14)1002–1006
   PubMed Web of Science ®Google Scholar
• Phillip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333(28)1540–1545
   PubMed Web of Science ®Google Scholar
• Benyunes M. C., Higuchi C., York A., et al. Immunotherapy with interleukin 2 with or without lym-phokine-activated killer cells after autologous hone marrow transplantation: a feasibility trial. Bone Marrow Transplant 1995; 16(2)283–288
   PubMed Web of Science ®Google Scholar
• Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Nelp W. B., Glenn S., Fisher D. R., Porter B., Matthews D. C., Gooley T., et al. Phase II trial of 1311-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1995; 346(8971)336–40
   PubMed Web of Science ®Google Scholar
• Haioun C., Lepage E., Gisselbrecht C., et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994; 12(12)2543–2551
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Van Putten W. L., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New Engl J Med 1995; 332(16)1045–1061
   PubMed Web of Science ®Google Scholar
• Martelli M., Vignetti M., Zinzani P. L., et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytara-bine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multi-center trial. J Clin Oncol 1996; 14(2)534–42
   PubMed Web of Science ®Google Scholar
• Philip T., Armitage J. O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316(24)1493–1498
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Fay J. W., Herzig R. H., et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75(4)831–838
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R. Treatment of aggressive non-Hodgkin's lymphoma with marrow transplantation. Marrow Trunsplant Review 1993; 3: 1–8
   Google Scholar
• Chopra R., Linch D. C., McMillan A. K., et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992; 81(2)197–202
   PubMed Web of Science ®Google Scholar
• Clift R. A., Buckner C. D., Appelbaum F. R., et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10(11)1723–1729
   PubMed Web of Science ®Google Scholar
• Sharp J. G., Kessinger A., Mann S., et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1966; 14(1)214–219
   Google Scholar
• Vose J. M., Bierman P. J., Anderson J. R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80(8)2142–2148
   PubMed Web of Science ®Google Scholar
• Goldie J. H. Modeling the process of drug resistance. Lung Cancer 1994; 10(Suppl 1)591–596
   Google Scholar
• Skipper H. E. Reasons for the success and failure in treatment of human leukemia with the drugs now employed in treating human leukemia. Cancer Chemotlzerapy Vol 1. University Microfilm International, Ann Arbor, Mich 1978
   Google Scholar
• Jaffrezou J. P., Chen G., Duran G. E., et al. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst 1994; 86(15)1152–1158
   PubMed Web of Science ®Google Scholar
• Skipper H. E. Experimental evaluation of potential anticancer agents. Cancer Chemother Rep 1974; 4: 137–145
   Google Scholar
• Herzig G. P., Herzig R. H. Current concepts in dose intensity and marrow transplantation. Acute Myelo-genous Leukemia: Progress and Controversies. Wiley-Liss. 1990; 333–344
   Google Scholar
• Lee W. J., Zimmerman T., Myers S., et al. Comparison of three mobilization regimens for peripheral blood progenitor cell rescue after high-dose chemotherapy. Prog Clin Biol Res 1994; 389: 421–427
   PubMedGoogle Scholar
• Goldschmidt H., Hegenbart U., Wallmeier M., et al. Peripheral blood progenitor cell mobilization in pretreated patients with multiple myeloma—A significantly lower B-cell content in leukapheresis products following 7 g/m2 compared to 4 g/m2 cyclophosphamide. Blood 1995; 86(10)402a, #1596
   Google Scholar
• Graham C. H., Kobayashi H., Stankiewicz, et al. Rapid acquisition of multicellnlar drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 1994; 86(13)975–982
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Anderson K. C., et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8(5)784–791
   PubMed Web of Science ®Google Scholar
• Bearman S. I., Appelbaum F. R., Back A., et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J. Clin Oncol 1989; 7(9)1288–1294
   Web of Science ®Google Scholar
• Traweek S. T., Slovak M. L., Nademanee P., et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84(3)957–963
   PubMed Web of Science ®Google Scholar
• Darrington D. L., Vose J. M., Anderson J. R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12(12)2527–2534
   PubMed Web of Science ®Google Scholar
• Stone R. M., Neuberg D., Soiffer R., et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12(12)2535–2542
   PubMed Web of Science ®Google Scholar
• Travis L. B., Curtis R. E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkins lymphoma. J Natl Cancer Inst 1995; 87(7)524–530
   PubMed Web of Science ®Google Scholar
• Moskowitz C. H., Portlock C. S., Simonaitis N. A., et al. The international prognostic index (IPI) predicts response and event free survival in an intent to treat autologous stem cell transplantation (ASCT) program for refractory and relapsed intermediate grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1996; 1270: 415, 15 #
   Google Scholar